SHANGHAI – The five month old GPCR Consortium – which brings together industry and academics to explore the G protein-coupled receptors (GPCRs) family of proteins – has added two new pharmaceutical members to its fold. It now counts Novo Nordisk AS and Merck & Co. Inc. as members in addition to founding members Amgen Inc., Ono Pharmaceutical Co. Ltd. and Sanofi SA. The partners provide not just funding to the research consortium's efforts.